Skip to main content
. 2010 Sep 7;28(29):4417–4424. doi: 10.1200/JCO.2009.26.4325

Fig 3.

Fig 3.

Predictive effect of the signature to adjuvant chemotherapy. Only high-risk group benefits from adjuvant chemotherapy. (A) High risk (microarray); (B) low risk (microarray); (C) high risk quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR); (D) low risk RT-qPCR.